The first GLP-1 drug, exenatide, was synthesized from exendin-4 , a peptide originally isolated from the saliva of the Gila monster lizard in the early 1990s and approved by the FDA in 2005.Over time, we got once-weekly versions (dulaglutide, semaglutide, etc.) and higher doses, which led to: Strong A1c lowering Substantial weight loss Cardiovascular benefits in high-risk patients with diabetes Where GLP-1s are clearly helpful Type 2 diabetes In type 2 diabetes, long-acting GLP-1 RAs: Lower A1c by roughly 11.5 percentage points Promote clinically meaningful weight loss Have low hypoglycemia risk Reduce heart attack and stroke in high-risk patients in multiple large trials For many with diabetes plus cardiovascular or kidney disease, a GLP-1 RA is now a core cardiometabolic drug , not just a glucose medication
M., Theodoroff, S
Federal law allows states to exclude agents used for weight loss from their Medicaid formularies so covering GLP-1s for obesity is optional, not required
It enhances the skin-brightening effects of glutathione
Improves renal function in animal models of kidney damage
Some clients feel a warm flush, slight chest pressure, or mild stomach discomfort during NAD+ infusions